3 High-Yield Dividend Stocks to Buy and Hold Forever (Hint: AbbVie Makes the List)

The article frames AbbVie (ABBV) as a dividend-focused healthcare name after Humira’s patent expiration, noting a ~2.5% starting yield and that dividends are ~48% of estimated 2026 earnings, implying a “cushion.” It contrasts Medtronic (MDT) and Bristol Myers Squibb (BMY): MDT has a ~48% payout ratio and potential upside via its Hugo robotics-assisted surgery system, while BMY yields ~4.3% but faces a patent cliff with analysts expecting ~-1% annualized earnings growth. Overall, the message is moderately supportive of healthcare dividend durability, with incremental upside tied to pipeline/robotics rather than immediate broad-market catalysts.

Analysis

The market takeaway is not “buy healthcare dividends,” but “pay up for durability, not yield.” ABBV and MDT can both re-rate if investors conclude their cash flows are self-funding and still growing; BMY looks statistically cheap, but cheapness is usually where the market prices in a future earnings gap, not a current one. In this tape, the higher-quality balance sheets and more credible reinvestment stories should attract defensive capital first, while pure yield names risk becoming duration-sensitive bond proxies if real rates stay elevated.

The second-order issue is competitive optionality. MDT’s robotics angle matters less as a near-term revenue driver than as a margin-mix and hospital lock-in story; if Hugo improves procedure economics, the valuation gap versus ISRG can narrow even without “winning” the category outright. For ABBV, the real question is whether post-Humira growth is broad enough to support a premium multiple; if not, the stock becomes a cash-return story rather than a compounder.

BMY is the contrarian setup: the low multiple can stay low unless pipeline data or guidance meaningfully changes the earnings bridge over the next 2-4 quarters. The dividend is not the issue; the issue is whether the Street will believe trough earnings are visible. Over 6-18 months, the biggest macro risk to all three names is a renewed backup in yields, which would compress multiples and make “safe income” less valuable relative to better growth elsewhere in healthcare.

Key Decisions for Investors

• Long ABBV / short BMY for 3-6 months: express quality vs value-trap dispersion; target a rerating if ABBV maintains double-digit earnings growth while BMY remains trapped in cliff optics. Exit if BMY delivers a credible pipeline de-risking or ABBV guidance slows materially.
• Accumulate MDT on weakness for a 6-12 month horizon as a laggard quality name with underappreciated optionality; best risk/reward comes after a quarter with stable procedure trends and any incremental evidence of Hugo utilization.
• Avoid initiating a fresh long in BMY solely on yield until the next 1-2 earnings prints confirm the post-cliff revenue bridge; treat it as a watchlist turnaround, not a core income position.
• If robotics adoption commentary improves, consider a small long MDT / short ISRG relative-value trade for 6-12 months; thesis is mean reversion in expectations, with ISRG valuation vulnerable if growth remains excellent but not accelerating.
• Set a macro alert on 10-year real yields: a sustained move higher would be a headwind to the whole dividend-healthcare basket and would likely be the cleanest reason to de-risk.